Technology | Treatment Planning | July 02, 2019

RaySearch Releases Version 9A of RayStation Treatment Planning System

Latest version of flagship TPS supports additional radiotherapy machines and treatment techniques, enhances integration with RayCare oncology information system

RaySearch Releases Version 9A of RayStation Treatment Planning System

July 2, 2019 — RaySearch announced the release of RayStation 9A, the latest version of its radiation therapy treatment planning system (TPS). RayStation 9A holds several improvements, supports additional machines and treatment techniques, as well as enhancements in the integration with the next-generation oncology information system (OIS) RayCare.

RayStation 9A adds support for treatment machines with dual-layer multi-leaf collimator (MLC) and non-rotating jaws, which are properties of the Varian Halcyon machine. This feature is one more step towards RaySearch’s goal to unify treatment planning for as many treatment delivery machines and systems as possible, eliminating complications and additional steps that arise from using multiple software systems.

Another improvement is the support for directly deliverable multi-criteria optimization for volumetric modulated arc therapy (VMAT) for Varian machines. This enables the same possibility for these machines as Elekta machines have had since the release of RayStation 8B.

New for this release is also the improved machine modelling for photons, allowing diagonal profiles in the beam commissioning module of RayPhysics. Extended possibility to export VSim plans for further use in any TPS is also new.

Improvements for proton therapy planning include caching of spot doses to speed up the optimization process. For carbon ion planning, support for Canon Medical machines have been added. The microdosimetric kinetic model (MKM) for calculation of radiobiological equivalent (RBE) dose is included. This is an important step to support carbon ion treatments in Japan, where most of the current carbon ion facilities are located. Support for connectivity with the interface IONTRIS used for Siemens carbon ion machines has also been added.

RayStation 9A also includes several general improvements, such as support for a 6D (six-dimensional) couch during planning. Enhancements in the integration with RayCare, such as automatic generation of treatment plans based on a patient’s diagnosis, are also included.

For more information: www.raysearchlabs.com

Related Content

Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr
Phase III clinical trial of men with a clinical suspicion of prostate cancer finds MRI with targeted biopsies to be more accurate at diagnosis and less intrusive than current standard
News | Magnetic Resonance Imaging (MRI) | February 08, 2021
February 8, 2021 — The results of a Phase III randomized clinical trial have shown that when it comes to detecting cl

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021
February 5, 2021 — A technique that delivers...
Real Time Imaging Technologies LLC iannounced that it has received U.S. Patent No. 10,898,070 IMAGING APPARATUS AND METHODS which covers the company’s methods for incorporating microlens into X-ray imaging detectors that enables significantly lower radiation dose without compromising image resolution.

Getty Images

News | Radiation Dose Management | February 05, 2021
February 5, 2021 — 
Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti

Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti

News | PET Imaging | February 03, 2021
February 3, 2021 — Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry recep